IPO registrations (S-1, F-1) · Registrants
OSIRIS THERAPEUTICS, INC.
- SEC CIK
- 1360886 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2006-05-12, last 2006-08-03; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2006-08-04; declared effective 2006-08-03
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- MD
- Business address
- 7015 ALBERT EINSTEIN DRIVE, Columbia, MD 21046
- EIN
- 71-0881115
- EDGAR entity type
- operating
- Insiders and CEO pay
- OSIRIS THERAPEUTICS, INC. on the corporate pages
Offering terms
- Proposed price range
- $11.00–$13.00 per share (S-1/A filed 2006-08-01)
- Final price
- $11.00 per share, within the range (424B4 filed 2006-08-04, an initial public offering)
- Shares sold
- 3,500,000
- Gross proceeds
- $38,500,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol OSIR
- Lead underwriters
- Jefferies
- Syndicate
- Lazard; Leerink Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: OSIRIS THERAPEUTICS, INC. EXACT (EIN (EXACT))
- Federal award recipient: OSIRIS THERAPEUTICS, INC. Fuzzy (name and state)
- Lobbying client: OSIRIS THERAPEUTICS Fuzzy (name and state)
- Lobbying client: OSIRIS THERAPEUTICS, INC. Fuzzy (name and state)
- Lobbying registrant: OSIRIS THERAPEUTICS Fuzzy (name and state)
- SEC filer: OSIRIS THERAPEUTICS, INC. EXACT (CIK (EXACT))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-05-12 | S-1 | S-1 (registration) | OSIRIS THERAPEUTICS, INC. | 0001047469-06-006938 ↗ |
| 2006-06-20 | S-1/A | S-1/A (amendment) | OSIRIS THERAPEUTICS, INC. | 0001047469-06-008601 ↗ |
| 2006-07-17 | S-1/A | S-1/A (amendment) | OSIRIS THERAPEUTICS, INC. | 0001047469-06-009631 ↗ |
| 2006-08-01 | S-1/A | S-1/A (amendment) | OSIRIS THERAPEUTICS, INC. | 0001047469-06-010178 ↗ |
| 2006-08-03 | S-1/A | S-1/A (amendment) | OSIRIS THERAPEUTICS, INC. | 0001047469-06-010340 ↗ |
| 2006-08-03 | EFFECT | EFFECT (declared effective) | OSIRIS THERAPEUTICS, INC. | 9999999995-06-001037 ↗ |
| 2006-08-04 | 424B4 | 424B4 (final prospectus) | OSIRIS THERAPEUTICS, INC. | 0001047469-06-010364 ↗ |
| 2008-01-31 | EFFECT | EFFECT (declared effective) | OSIRIS THERAPEUTICS, INC. | 9999999995-08-000382 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2006-08-01 | S-1/A | registration statement | $11.00–$13.00 | 3,500,000 | - | Nasdaq OSIR | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2006-08-03 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2006-08-04 | 424B4 | final prospectus | $11.00 | 3,500,000 | $38,500,000 | Nasdaq OSIR | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| BARNHILL GREGORY HURD | Director | 8 | 2006–2012 | ||
| Carmitchel Harry E | Officer | Chief Operating Officer | 16 | 2006–2008 | |
| Claiborne Cary J | Officer | Chief Financial Officer | 5 | 2006–2007 | |
| Debrabandere Lode | Officer | President & CEO; Senior Vice President; Vice President | 14 | 2006–2016 | |
| FENDER EARL R | Officer; Other | Vice President | 4 | 2006–2008 | |
| FRIEDLI PETER | Director; Director,TenPercentOwner; Director,TenPercentOwnerOther | 22 | 2006–2019 | ||
| Gutzwiller Felix | Director | 9 | 2006–2014 | ||
| JACOBY PHILIP R JR | Officer | Chief Financial Officer; Controller; Interim Chief Financial Off.; Principal Accounting Officer; Vice President of Finance | 19 | 2006–2016 | |
| Mills C Randal | Director,Officer | President & CEO | 13 | 2006–2013 | |
| MOYES JAY M | Director | 9 | 2006–2014 | ||
| VENTURETEC INC | Other; TenPercentOwner | 9 | 2006–2018 | ||
| Williams Michelle LeRoux | Officer | Chief Scientific Officer; Vice President - Development | 12 | 2007–2014 | |
| Hunt Richard W | Officer | Chief Financial Officer | 3 | 2008–2009 | |
| Neumayer Matthew Paul | Officer | Principal Accounting Officer | 11 | 2009–2014 | |
| Potter Stephen W | Officer | Senior Vice President | 3 | 2011–2012 | |
| Klingemann Hans-Georg | Director | 3 | 2012–2014 | ||
| Czworka Frank D Jr | Officer | Vice President | 4 | 2014–2016 | |
| LAW GREGORY IVAN | Officer | Principal Accounting Officer | 2 | 2014–2015 | |
| Mollo Adrian Patrick | Officer | General Counsel | 1 | 2014 | |
| Hopper Jonathan Mark | Officer | Chief Medical Officer | 3 | 2014–2016 | |
| Danilkovitch Alla | Officer | Chief Scientific Officer | 5 | 2015–2019 | |
| Huwyler Yves | Director | 1 | 2015 | ||
| Montgomery Bobby Dwayne | Director,Officer; Officer | Chief Business Officer; Chief Executive Officer | 4 | 2015–2016 | |
| DRESNER DAVID A | Officer | Interim President & CEO | 9 | 2016–2017 | |
| Avendano Rodrigo Alberto | Officer | Chief Medical Officer | 2 | 2016–2017 | |
| Sommer Uwe | Director | 1 | 2017 | ||
| CHANG LINDA L | Officer | Chief Financial Officer | 3 | 2017–2018 | |
| Keefer Jason | Officer | Chief Commercial Officer; Interim President and CEO; Interim President & CEO | 4 | 2017–2019 | |
| Palczuk Linda | Officer | President & CEO | 2 | 2017 | |
| WHITE DAVID L | Director | 1 | 2017 | ||
| Knapp Thomas J | Director | 1 | 2018 | ||
| Miesch Willi | Director | 1 | 2018 | ||
| VERNAL SHAUNA L | Officer | Chief Legal Officer; Chiel Legal Officer | 2 | 2018 | |
| Rogers Joel David | Officer | Interim CFO | 1 | 2018 | |
| NEW VENTURETEC AG | TenPercentOwner | 1 | 2018 | ||
| Reinhart Charles A. III | Director | 1 | 2018 | ||
| Tom Samson | Officer | President & CEO | 1 | 2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Federal award recipient | OSIRIS THERAPEUTICS, INC. | MD | Federal spending (USAspending) | name and state |
| IPO registrant | BROADWING CORP | MD | IPO registrations (S-1, F-1) | same street address and ZIP code, 7015 ALBERT EINSTEIN DR 21046 (FUZZY: a shared address, not proof of a shared organization) |
| Lobbying client | OSIRIS THERAPEUTICS | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | OSIRIS THERAPEUTICS, INC. | MD | Federal lobbying (LDA) | name and state |
| Lobbying registrant | OSIRIS THERAPEUTICS | MD | Federal lobbying (LDA) | name and state |
| Paying company | Osiris Therapeutics Inc. | MD | Open Payments (drug and device company payments) | name and state |
| Patent assignee | OSIRIS THERAPEUTICS, INC. | MD | Patents (USPTO) | name and state |
| SEC filer | OSIRIS THERAPEUTICS, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Osiris Therapeutics, Inc. | MD | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | OSIRIS THERAPEUTICS, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.